New therapeutic options are evolving in the IBD therapeutic field, including early diagnosis and intervention, treat to target strategy and control of biomarkers. Novel potentially effective therapies are appearing almost every year but being in a highly competitive field not all of them are able to achieve the study endpoints. The current trend in IBD drug development is shift to effective oral therapy which still has pros and cons and subsequently, makes conducting of clinical trials more challenging than 10 years ago.